Choose Your Country or Region

Breast Cancer

Modeling Agent

N-Nitroso-N-methylurea

Chemoprevention

SERMs: Tamoxifen; 4-Hydroxytamoxifen; (Z)-4-Hydroxytamoxifen; Bazedoxifene (WAY-140424) HCl; Raloxifene HCl; Toremifene Citrate; Clomifene citrate; Lasofoxifene Tartrate

Aromatase Inhibitors: Exemestane; Anastrozole; Letrozole; Fadrozole; Obacunone; Oleuropein

Drugs Approved (A)

HER2: Trastuzumab-deruxtecan; Neratinib; Trastuzumab-Emtansine（T-DM1）; Lapatinib Ditosylate; Tucatinib; Trastuzumab; Pertuzumab; Margetuximab

Estrogen/progestogen Receptor: Fulvestrant; Elacestrant (RAD1901) Dihydrochloride; Tamoxifen Citrate; Toremifene Citrate; Megestrol Acetate

CDK: Abemaciclib; LEE011; Palbociclib

Microtubule Associated: Nab-Paclitaxel; Docetaxel; Eribulin Mesylate; Ixabepilone

Aromatase: Letrozole; Anastrozole; Exemestane

Drugs Approved (B)

DNA/RNA Synthesis: Gemcitabine Hydrochloride; 5-Fluorouracil; Capecitabine; Cyclophosphamide

mTOR: RAD001

Chemotherapy: Doxorubicin (Adriamycin) Hydrochloride; Epirubicin HCl; Vinblastine sulfate; Thiotepa

PI3K: Alpelisib

PD-1/PD-L1: Pembrolizumab; Atezolizumab

PARP: AZD2281; BMN-673

DHFR: Methotrexate disodium

Bone resorption factor: Pamidronate Disodium

Trop-2: Sacituzumab govitecan

Chemotherapy Regimens

AC: Doxorubicin (Adriamycin) Hydrochloride; Cyclophosphamide

AC-T: Doxorubicin (Adriamycin) Hydrochloride; Cyclophosphamide; Paclitaxel

CAF: Cyclophosphamide; Doxorubicin (Adriamycin) Hydrochloride; 5-Fluorouracil

CMF: Cyclophosphamide; Methotrexate; 5-Fluorouracil

FEC: 5-Fluorouracil; Epirubicin HCl; Cyclophosphamide

TAC: Docetaxel; Doxorubicin (Adriamycin) Hydrochloride; Cyclophosphamide

CAVP: Cyclophosphamide; Doxorubicin; Vincristine; Prednisone

NX: Vinorelbine ditartrate; Capecitabine

Endocrine Therapy

Aromatase Inhibitor: Exemestane; Anastrozole; Letrozole; Fadrozole; Obacunone; Oleuropein

SERMs: Tamoxifen; 4-Hydroxytamoxifen; (Z)-4-Hydroxytamoxifen; Bazedoxifene (WAY-140424) HCl; Raloxifene HCl; Toremifene Citrate; Clomifene citrate; Lasofoxifene Tartrate

SERDs: Amcenestrant; Elacestrant (RAD1901) Dihydrochloride; Brilanestrant

ER Antagonist: Fulvestrant; Endoxifen HCl; Amcenestrant; Camizestrant; PHTPP; H3B-5942; Enclomiphene Citrate

Immune Checkpoint Inhibitors

PD-1: Pembrolizumab; Dostarlimab; Cemiplimab; Camrelizumab; Sintilimab; Nivolumab; Serplulimab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CTLA-4: Nurulimab; Zalifrelimab; Quavonlimab; Ipilimumab; Tremelimumab

Anti-Angiogenesis ^[1]

Anti-VEGF: Bevacizumab; Ramucirumab; Sorafenib; Sunitinib; Ponatinib; Apatinib; Tivozanib

TKIs: Sorafenib; Sunitinib; Vandetanib; Axitinib; Pazopanib; Cediranib

Targeted Therapy

HER2: Afatinib; AC480; CP-724714; CUDC-101; Trastuzumab; Pertuzumab; Margetuximab; Trastuzumab-deruxtecan

MUC1: GO-203 TFA; Clivatuzumab; Cantuzumab; Gatipotuzumab; Clivatuzumab-MMAE

TROP-2: Sacituzumab; Datopotamab; Sacituzumab govitecan; Datopotamab deruxtecan

PARPi: AZD2281; BMN-673

CDKi: Abemaciclib; LEE011; Palbociclib

mTORi: RAD001; KU-0063794; WYE-354

TKIs: Lapatinib; Neratinib; Tucatinib

PAK1: PF-3758309; NVS-PAK1-1

RAGE: FPS-ZM1; Azeliragon

mAb & ADC

PD-1: Pembrolizumab; Nivolumab; Camrelizumab; Cemiplimab; Sintilimab; Dostarlimab; Serplulimab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CTLA-4: Ipilimumab; Tremelimumab; Nurulimab; Zalifrelimab; Quavonlimab

HER2: Trastuzumab; Trastuzumab-deruxtecan; Pertuzumab; Margetuximab

MUC1: Clivatuzumab-MMAE; Clivatuzumab; Cantuzumab; Gatipotuzumab

TROP-2: Sacituzumab; Sacituzumab govitecan; Datopotamab deruxtecan; Datopotamab

Triple-Negative ^[2]

Single-Agent Chemotherapy: Paclitaxel; Cisplatin; Doxorubicin; Capecitabine; Eribulin Mesylate; Vinorelbine ditartrate; Gemcitabine

PARPi: AZD2281; BMN-673

WEE1i ^[3]: PD0166285; Adavosertib; Debio 0123; Azenosertib

RAGE ^[4]: FPS-ZM1; Azeliragon

JAK1/2 ^[5]: Ruxolitinib

HR+/HER2- ^[2]

Aromatase Inhibitor: Exemestane; Anastrozole; Letrozole; Fadrozole; Obacunone; Oleuropein

CDK4/6 Inhibitor: Abemaciclib; Palbociclib; LEE011

Endocrine Therapy: Fulvestrant; Exemestane; Tamoxifen

PARPi: AZD2281; BMN-673

mTORi: RAD001

HR+/HER2+ ^[6]

Aromatase Inhibitor: Exemestane; Anastrozole; Letrozole; Fadrozole; Obacunone; Oleuropein

SERMs: Tamoxifen; 4-Hydroxytamoxifen; (Z)-4-Hydroxytamoxifen; Bazedoxifene (WAY-140424) HCl; Raloxifene HCl; Toremifene Citrate; Clomifene citrate; Lasofoxifene Tartrate

SERDs: Amcenestrant; Elacestrant (RAD1901) Dihydrochloride; Brilanestrant

HER2-Targeted mAb: Trastuzumab; Trastuzumab-deruxtecan; Pertuzumab; Margetuximab; Trastuzumab Emtansine（T-DM1）; Disitamab vedotin; Trastuzumab MMAE

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Tyrosine Kinase Inhibitor Library

PI3K/Akt Inhibitor Library

References

https://pubmed.ncbi.nlm.nih.gov/35281942/
https://pubmed.ncbi.nlm.nih.gov/30667505/
https://pubmed.ncbi.nlm.nih.gov/37582853/
https://pubmed.ncbi.nlm.nih.gov/37443146/
https://pubmed.ncbi.nlm.nih.gov/37979170/
https://pubmed.ncbi.nlm.nih.gov/37258523/